|
|
||||||||
1Centre de Recherche en Cancérologie de l'Université Laval, Centre Hospitalier Universitaire de Québec, Centre de Recherche du Pavillon l'Hôtel-Dieu de Québec, Canada G1R 2J6; 2Institut de Pharmacologie, Faculté de Médecine, Université de Sherbrooke, Sherbrooke, Canada J1H 5N4; 3Faculté de Pharmacie, Université de Montréal, Montréal, Québec, Canada H3C 3J7; and 4Institute of Pharmacology, University of Ferrara, Ferrara, 44100, Italy
Submitted 23 December 2002 ; accepted in final form 17 March 2003
It has been recently claimed that the human B1 receptors for kinins bind angiotensin-converting enzyme (ACE) inhibitors via a potential zinc-binding domain and are pharmacologically stimulated by these drugs. We verified whether ACE inhibitors stimulate B1 receptors in vitro. The isolated rabbit aorta or mouse stomach responded by negligible contractions to the application of captopril, enalaprilat, or zofenoprilat. The human isolated umbilical vein also failed to respond to enalaprilat. All of these preparations were responsive to the B1 receptor agonists des-Arg9-bradykinin (BK) or Lys-des-Arg9-BK. Furthermore, enalaprilat applied continuously had no significant interaction with the effects of Lys-des-Arg9-BK on the rabbit aorta. Enalaprilat failed to stimulate [3H]arachidonate release, translocate the receptors (confocal microscopy), or stimulate ERK1/2 phosphorylation (immunoblot) in HEK-293 cells stably expressing the rabbit B1 receptor conjugated to yellow fluorescent protein. The phospho-ERK1/2 content of arterial smooth muscle cells of human or rabbit origin was increased by treatment with Lys-des-Arg9-BK but not with enalaprilat. ACE inhibitors do not act as bona fide agonists of the kinin B1 receptors.
enalaprilat; angiotensin II; des-Arg9-bradykinin
This article has been cited by other articles:
![]() |
J. Xu, O. A. Carretero, E. G. Shesely, N.-E. Rhaleb, J. J. Yang, M. Bader, and X.-P. Yang The kinin B1 receptor contributes to the cardioprotective effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in mice Exp Physiol, March 1, 2009; 94(3): 322 - 329. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-P. Fortin, L. Gera, J. Bouthillier, J. M. Stewart, A. Adam, and F. Marceau Endogenous Aminopeptidase N Decreases the Potency of Peptide Agonists and Antagonists of the Kinin B1 Receptors in the Rabbit Aorta J. Pharmacol. Exp. Ther., September 1, 2005; 314(3): 1169 - 1176. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. G. Pelorosso, P. T. Brodsky, C. L. Zold, and R. P. Rothlin Potentiation of des-Arg9-Kallidin-Induced Vasoconstrictor Responses by Metallopeptidase Inhibition in Isolated Human Umbilical Artery J. Pharmacol. Exp. Ther., June 1, 2005; 313(3): 1355 - 1360. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Xu, O. A. Carretero, Y. Sun, E. G. Shesely, N.-E. Rhaleb, Y.-H. Liu, T.-D. Liao, J. J. Yang, M. Bader, and X.-P. Yang Role of the B1 Kinin Receptor in the Regulation of Cardiac Function and Remodeling After Myocardial Infarction Hypertension, April 1, 2005; 45(4): 747 - 753. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. M. F. Leeb-Lundberg, F. Marceau, W. Muller-Esterl, D. J. Pettibone, and B. L. Zuraw International Union of Pharmacology. XLV. Classification of the Kinin Receptor Family: from Molecular Mechanisms to Pathophysiological Consequences Pharmacol. Rev., March 1, 2005; 57(1): 27 - 77. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |